We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

8 hedge funds and large institutions have $187K invested in Oasmia Pharmaceutical AB in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more funds holding

Funds holding: 5 → 8 (+3)

42% less capital invested

Capital invested by funds: $323K → $187K (-$136K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$60.2K
2
OMC
Old Mission Capital
Illinois
+$28.6K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$480

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$123K
2
Deutsche Bank
Deutsche Bank
Germany
-$23.3K
3
UBS Group
UBS Group
Switzerland
-$1.14K
4
Morgan Stanley
Morgan Stanley
New York
-$3

OASM Hedge Fund Activity: Q1 2019 in Review

8 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q1 2019, worth a combined $187K — down 42% from $323K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new OASM positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $60.2K. The largest seller was Jane Street, cutting an estimated $123K.

  • 8 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q1 2019, up from 5 in Q4 2018.
  • Funds reported $187K of Oasmia Pharmaceutical AB stock for Q1 2019, down 42% quarter-over-quarter.
  • 3 funds opened new Oasmia Pharmaceutical AB positions in Q1 2019 and 0 closed out, a net change of +3 holders.
  • The largest Oasmia Pharmaceutical AB buyer in Q1 2019 was Susquehanna International Group, an estimated $60.2K added.
  • The largest Oasmia Pharmaceutical AB seller in Q1 2019 was Jane Street, an estimated $123K sold.

Based on aggregated 13F filings for Q1 2019.